Matthias Versele joins the Centre for Drug Design & Discovery as Director of Drug Discovery Biology
The Centre for Drug Design & Discovery (CD3) is pleased to announce the appointment of Dr. Matthias Versele as Director of Drug Discovery Biology. Within CD3, Matthias will play a key role in the identification and selection of new investment opportunities and in defining the strategic directions of CD3. Together with his team, he will have the responsibility to build a sustainable flow of new drug discovery projects and will drive the identification and development of new drugs based on innovative science from our partners.
CD3 and Rega Institute hunt for Zika virus inhibitors with the support of EU
In the context of the ZIKAlliance consortium, the KU Leuven Laboratory of Virology, led by Prof. Johan Neyts, will join forces with the Leuven Centre for Drug Design & Discovery (CD3) led by Dr. Patrick Chaltin to develop highly potent and safe antiviral drugs to treat or prevent infections with the Zika virus. The team led by Prof. Catherine Verfaillie will be involved in the study of infection of brain cells with the Zika virus, using stem-cell derived neuronal cultures. The teams of Prof. Anne-Mieke Vandamme, Prof. Philippe Lemey, and Prof. Jelle Matthijnssens will join forces to investigate the genetic diversity, molecular evolution, and geographic migration of Zika viruses and to assess whether other viral (co-)infections affect Zika virus-associated diseases.
CD3 closes 60 million euro fund to turn academic research into new medicines.
The Centre for Drug Design & Discovery (CD3) has launched a 60 million euro fund to turn innovative biomedical research of academic institutions and small companies into drugs that improve and extend people’s lives. Following on previous investments in 2006 and 2010, KU Leuven Research & Development and the European Investment Fund (EIF) jointly provide the capital for this third CD3 fund. Both partners thereby strongly confirm their belief in CD3’s mission to translate innovative (academic) science into promising drug discovery programs that are well qualified for further development by pharmaceutical or biotech companies. The new fund will allow CD3 to bring potential drugs into clinical development together with industrial partners, as well as on its own.
Deal with Novartis for the development of new rhinovirus inhibitors.
VIB and CD3 join forces with AstraZeneca for the development of MALT1 inhibitors
VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.
Wellcome Trust and KU Leuven collaborate with Janssen for development of dengue antiviral drugs
Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the prevention and treatment of dengue infection.